NeuroQuant is new software that improves the early detection and treatment of dementia and Alzheimer’s disease (AD). It is a brain imaging technique. It precisely measures the brain atrophy (shrinkage) by measuring the size of the hippocampus and other brain structures that typically deteriorate with these disorders. This information helps doctors make a diagnosis and follow the progression of the disease.
NeuroQuant evaluates the patient’s MRI for brain atrophy and compares the results to an FDA-approved database of people of the same age that have healthy brains. It can help provide an early warning for patients who have Mild Cognitive Impairment (MCI). Studies have found a correlation between hippocampus size and AD onset.
NeuroQuant can monitor changes in the atrophy over time to determine if and how quickly the disease is progressing. It also may help to measure the impact of treatments and identify those patients most likely to benefit from aggressive intervention.
Although normal-sized brain structures can’t rule out dementia, high-functioning patients concerned about mild, but increasing, memory loss are likely to be reassured by results in the normal range.